Back to peptides

KPV

aka alpha-MSH(11-13), Lys-Pro-Val, KPV tripeptide

Anti-inflammatoryGut HealthSkin RepairAnti-inflammatoryImmune Modulator

Last reviewed April 27, 2026 by Doserr editorial team · 12 references on this page

Information on this page is sourced from published research and is for educational purposes only. It does not constitute medical advice.

TL;DR

  • What it is: A synthetic tripeptide (alpha-MSH positions 11-13) made of lysine, proline, and valine.
  • What it's used for: Studied for gut inflammation in rodent colitis models, all evidence is animal or in vitro only.
  • Evidence level:limitedNo human clinical trials published for any indication.

Dose at a glance

BeginnerCommonHigher end
Per dose250 mcg250-500 mcg500 mcg - 1 mg
Daily total250 mcg250-500 mcg1-2 mg
ScheduleOnce daily1-2x daily2x daily
Cycle length4 weeks4-8 weeks8-16 weeks

Synthesized from community-reported ranges. Not a recommendation. Route varies by compound — see Common route in What people report below.

Half-life
Not characterized in any published human pharmacokinetic study. Preclinical data suggest some resistance to aminopeptidase degradation due to the proline residue at position 2.
Typical dose range
Doses below are from published research, not recommendations. Rodent oral colitis studies: KPV in drinking water at approximately 100 micromolar (approx. 205 mcg/day, Dalmasso et al. 2008, PMID 18061177). Nanoparticle delivery mouse studies: approx. 16 mcg/kg/day. No human dosing data exist.
Route
Oral (drinking water) in rodent colitis models, intraperitoneal in peritonitis models, topical in skin inflammation models.
Evidence tier
limited

Animal or in-vitro studies only — no published human efficacy data.

What the research shows

Each topic links to the studies behind it. Click a topic to expand.

What we don't know yet

  1. No human clinical trial data exist, all efficacy findings are from rodent models or cell culture
  2. Human pharmacokinetics not characterized, no published peer-reviewed PK study in humans
  3. Effective human dose range unknown, rodent doses cannot be directly extrapolated to humans without PK data
  4. Oral vs. injectable bioavailability in humans not established, community claims of oral activity are not supported by published human data
  5. Long-term safety unstudied in humans or in any published long-term animal study
  6. Not FDA-approved, no active drug development program or registered clinical trial as of mid-2025

Run a calculation for this peptide

Reconstitution math, both directions.

Track this peptide

Log every dose, see your history, and save this protocol with one click.